← FDA DRUG APPROVALS

FDA ANDA · ANDA065007

CEPHALEXIN

Sponsor: SUN PHARM INDS LTD

APPLICATION
ANDA065007
TYPE
ANDA
ORIGINAL APPROVAL
1999-09-16
LATEST ACTION
2004-07-02
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CEPHALEXINDiscontinued
CEPHALEXIN EQ 250MG BASE · CAPSULE · ORAL
CEPHALEXINDiscontinued
CEPHALEXIN EQ 500MG BASE · CAPSULE · ORAL

Approval history

2004-07-02Labeling · Supplement 15AP
2003-11-03Labeling · Supplement 11AP
2003-11-03Labeling · Supplement 10AP
2001-09-05Manufacturing (CMC) · Supplement 5AP
2001-09-05Manufacturing (CMC) · Supplement 6AP
2000-07-18Manufacturing (CMC) · Supplement 3AP
2000-07-18Manufacturing (CMC) · Supplement 2AP
2000-06-29Manufacturing (CMC) · Supplement 4AP
2000-03-01Manufacturing (CMC) · Supplement 1AP
1999-09-16OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →